Areas of Interest

Ophthalmology

Cataracts

Band Keratopathy

CATARACTS

Cataracts are calcium lipid/protein aggregates that increase the opacity of the human lens and lead to impaired vision. It is the #1 cause of world blindness and 99% of all adults over 50 years of age, will get cataracts in their lifetime. It is the single largest line item in US Medicare budget. The current standard of care is surgery, typically reimbursed only for late-stage cataracts.

Diagnosed in USA

27.8M

Clinical Phase

PHASE 2

COMPLETED

Opacity of the lens in early to moderate stage cataracts impairs vision significantly. Patients often see blinding lights and have foggy vision such as in the picture to the left.

#1

leading Cause of blindness globally

Cataract based vision loss starts around age 40, and the average age of surgery is 72 with vision loss increasing with each year. Typical symptoms of pre-surgical cataracts include significantly reduced vision especially in dim light, loss of color perception, and glare.

Mesopic Improvement

REFERENCE: PMID 39098755

 A sub–analysis of a multi–center FDA Phase I/II trialshowed that the active group showed a clinically and statistically significant improvement in low light visual function as measured by mesopic (low light) contrasts sensitivity testing.

Reduced Average Lens Density with C-KAD

Cataracts are a clouding of the human lens. Another sub–analysis that imaged the lens using Scheimpflug Imaging, also showed that compared to the placebo, the active group of patients showed reduced lens clouding (density).

Lens Density Images
Lens Density Graph
REFERENCE: PMID 39098755
At Day 120, as compared to Placebo, C-KAD showed statistically significant improvement in improving lens clarity and therefore reducing light scattering

eye drops target pre-surgical cataracts
(between 40 – 72 years)

eye-chart<br />

Sub-analysis of a US Phase I/II trial in early-to-moderate cataracts showed that Livionex C-KAD Eye Drops showed improved mesopic (low light) contrast sensitivity and improved lens clarity.

Clinical Study

Finalizing Phase 3 Trials for the cataract indication in consultation with the FDA

eye icon<br />

In vitro and in vivo pre-clinical data shows that the eye drop may have efficacy in other therapeutic areas including diabetic retinopathy and optic nerve protection.

BAND KERATOPATHY

Band Keratopathy is a calcific band in the cornea that causes extreme discomfort, pain, and impaired vision. Current standard of care is surgical debridement of the corneal epithelium, then using EDTA to remove the calcific deposits in the Bowman’s layer.

Annual Incidence in USA

< 100K

Clinical Phase

PHASE 3

The image on the left displays a band-shaped, horizontal opacity that has grown from the peripheral cornea towards the central cornea.

FASTER APPROVALS

AN APPROVAL IN BAND KERATOPATHY WOULD LEAD TO EXPEDITED NDAs IN OTHER OCULAR INDICATIONS.

band keratopathy

The image above displays a band-shaped, horizontal opacity that has grown from the peripheral cornea towards the central cornea.

FASTER APPROVALS

AN APPROVAL IN BAND KERATOPATHY WOULD LEAD TO EXPEDITED NDAs IN OTHER OCULAR INDICATIONS.